Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | QDPR | P09417 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 4/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD5 | P21918 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17072665 | 0.90 | DRD3 (0.53) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL22805478 | 0.86 | SIGMAR1 (0.47) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| SCHEMBL18616729 | 0.85 | DRD2 (0.60) | DRD2QDPRDRD3DRD1DRD4 | |
| SCHEMBL20671891 | 0.83 | DRD2 (0.47) | DRD2SIGMAR1QDPRDRD3DRD1 | |
| SCHEMBL5620353 | 0.83 | PRMT6 (0.47) | DRD2QDPRDRD3DRD1DRD4 | |
| SCHEMBL5666205 | 0.81 | DRD2 (0.49) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| SCHEMBL25377908 | 0.80 | QDPR (0.48) | DRD2QDPRDRD3 | |
| SCHEMBL31263811 | 0.80 | QDPR (0.48) | DRD2QDPRDRD3 | |
| SCHEMBL4511164 | 0.80 | DRD2 (0.51) | DRD2SIGMAR1DRD3 | |
| SCHEMBL3680708 | 0.79 | SIGMAR1 (0.43) | DRD2SIGMAR1DRD3DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| WO-2017040449-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | DRD2 4834/4885SIGMAR1 397/4885QDPR 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.